| Project/Area Number |
17590784
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Hamamatsu University School of Medicine |
|---|
Principal Investigator |
SUDA Takafumi Hamamatsu University School of Medicine, 2nd Division of Internal Medicine, Assistant Professor (30291397)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
CHIDA Kingo Hamamatsu University School of Medicine, 2nd Division of Internal Medicine, assistant Professor (40197611)
NAGATA Toshi Hamamatsu University School of Medicine, School of Nursing, Professor (90275024)
|
|---|
| Project Period (FY) |
2005 – 2006
|
| Project Status |
Completed (Fiscal Year 2006)
|
| Budget Amount *help |
¥3,500,000 (Direct Cost: ¥3,500,000)
Fiscal Year 2006: ¥1,500,000 (Direct Cost: ¥1,500,000)
Fiscal Year 2005: ¥2,000,000 (Direct Cost: ¥2,000,000)
|
|---|
| Keywords | Dendritic cell / Mucosal vaccine / Listeria / リステリア / 結核 / ワクチン |
|---|
| Research Abstract |
The present study was conducted to develop an effective mucosal cell-vaccine against infection of intracellular pathogen. Bone-marrow derived mouse dendritic cells were treated with LPS for 16 hrs, and pulsed with dominant cytotoxic T cell (CTL) epitope, LLO91-99, derived from lysteriolysin O of Listeria monocytogenesis (LM). Then, LLO-loaded dendritic cells were intratracheally instilled. Tracheal injection of LLO-loaded dendritic cells induced LLO-specific CTL determined by tetramers, and LLO-specific IFN-gamma production from regional lymph nodes. In a mouse model of pulmonary LM infection, vaccinated mouse showed a significant decrease in bacterial doses compared with naive mouse. Moreover, this dendritic cell-vaccine protected them from lethal LM infection. Taken together, these results suggest that intratracheal administration of dendritic cells loaded with a dominant CTL epitope against intracellular pathogen is an effective mucosal vaccine, which induces protective immunity the mucosal sites as well as systemic immunity.
|
